-
-
Precision Health Ecosystem FutureTech A Kinase Inhibitor that Induces Degradation of MYC Oncoprotein
This technology is a development drug lead aiming to meet the medical needs of patients with small cell lung cancer. Through disturbing MYC-Aurora A interaction and inducing degradation of MYC oncoprotein, this bioavailable kinase inhibitor could serve as a potential treatment entity for SCLC.
-
-
-
FutureTech 早期非小細胞肺癌組織內腫瘤浸潤白血球的免疫特性分析。
In the current of study, cell subsets, cell proportionsthe immune function of tumors-infiltrating leukocytes were used to indicate the features of tumor immune microenvironment in non-small cell lung cancers (NSCLCs) with different type of EGFR genetic alteration.
-
- 1
